Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CASR | P41180 | 1/20 | 0.51 |
| ▸ | SELP | P16109 | 1/20 | 0.51 |
| ▸ | SELE | P16581 | 1/20 | 0.51 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289827 | 0.86 | KDM4E (0.64) | SMN1; SMN2KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL7824993 | 0.85 | KMT2A (0.63) | SMN1; SMN2KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL2449980 | 0.82 | KDM4E (0.68) | SMN1; SMN2KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL4294304 | 0.82 | ALDH1A1 (0.68) | SMN1; SMN2KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL178162 | 0.80 | CASR (0.64) | SMN1; SMN2KDM4EALDH1A1LMNACASR | |
| SCHEMBL6003048 | 0.80 | CASR (0.64) | SMN1; SMN2KDM4EALDH1A1LMNACASR | |
| SCHEMBL15183763 | 0.79 | KMT2A (0.56) | SMN1; SMN2KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL16404495 | 0.79 | KMT2A (0.69) | SMN1; SMN2KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL30810149 | 0.79 | ALDH1A1 (0.63) | SMN1; SMN2KDM4EALDH1A1LMNACASR | |
| SCHEMBL15575684 | 0.77 | L3MBTL1 (0.57) | SMN1; SMN2KDM4EALDH1A1LMNASHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426466-B2 | Compositions and methods for enhancing active agent absorption | NEXUS PHARMA, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2150243-A2 | COMPOSITIONS AND METHODS FOR ENHANCING ACTIVE AGENT ABSORPTION | Nexus Pharma, Inc. (US) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008144690-A2 | COMPOSITIONS AND METHODS FOR ENHANCING ACTIVE AGENT ABSORPTION | NEXUS PHARMA, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20070269500-A1 | Compositions and methods for enhancing active agent absorption | NEXUS PHARMA, INC. | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070269500-A1 | Compositions and methods for enhancing active agent absorption | FABP2, SLC10A2, SI | SMN1; SMN2 1589/4885KDM4E 4357/4885ALDH1A1 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.